1. Home
  2. IMCR vs NIC Comparison

IMCR vs NIC Comparison

Compare IMCR & NIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • NIC
  • Stock Information
  • Founded
  • IMCR 2008
  • NIC 2000
  • Country
  • IMCR United Kingdom
  • NIC United States
  • Employees
  • IMCR N/A
  • NIC N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • NIC Major Banks
  • Sector
  • IMCR Health Care
  • NIC Finance
  • Exchange
  • IMCR Nasdaq
  • NIC Nasdaq
  • Market Cap
  • IMCR 1.7B
  • NIC 1.8B
  • IPO Year
  • IMCR 2021
  • NIC N/A
  • Fundamental
  • Price
  • IMCR $33.50
  • NIC $122.84
  • Analyst Decision
  • IMCR Buy
  • NIC Buy
  • Analyst Count
  • IMCR 9
  • NIC 3
  • Target Price
  • IMCR $62.38
  • NIC $145.33
  • AVG Volume (30 Days)
  • IMCR 350.0K
  • NIC 100.9K
  • Earning Date
  • IMCR 11-06-2025
  • NIC 10-23-2025
  • Dividend Yield
  • IMCR N/A
  • NIC 1.04%
  • EPS Growth
  • IMCR N/A
  • NIC 18.84
  • EPS
  • IMCR N/A
  • NIC 9.34
  • Revenue
  • IMCR $356,145,000.00
  • NIC $375,962,000.00
  • Revenue This Year
  • IMCR $29.99
  • NIC N/A
  • Revenue Next Year
  • IMCR $8.85
  • NIC $4.83
  • P/E Ratio
  • IMCR N/A
  • NIC $13.15
  • Revenue Growth
  • IMCR 26.78
  • NIC 9.68
  • 52 Week Low
  • IMCR $23.15
  • NIC $97.90
  • 52 Week High
  • IMCR $39.33
  • NIC $141.92
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 49.73
  • NIC 38.46
  • Support Level
  • IMCR $31.36
  • NIC $116.42
  • Resistance Level
  • IMCR $34.18
  • NIC $130.78
  • Average True Range (ATR)
  • IMCR 1.38
  • NIC 4.57
  • MACD
  • IMCR -0.00
  • NIC -0.69
  • Stochastic Oscillator
  • IMCR 60.51
  • NIC 32.16

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About NIC Nicolet Bankshares Inc.

Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.

Share on Social Networks: